Efficiency of CYP2C9 Genetic Test Representation for Automated Pharmacogenetic Decision Support

OBJECTIVES We investigated the suitability of representing discrete genetic test results in the electronic health record (EHR) as individual single nucleotide polymorphisms (SNPs) and as alleles, using the CYP2C9 gene and its polymorphic states, as part of a pilot study. The purpose of our investigation was to determine the appropriate level of data abstraction when reporting genetic test results in the EHR that would allow meaningful interpretation and clinical decision support based on current knowledge, while retaining sufficient information in order to enable reinterpretation of the results in the context of future discoveries. METHODS Based on the SNP & allele models, we designed two separate lab panels within the laboratory information system, one containing SNPs and the other containing alleles, built separate rules in the clinical decision support system based on each model, and evaluated the performance of these rules in an EHR simulation environment using real-world scenarios. RESULTS Although decision-support rules based on allele model required significantly less computational time than rules based on SNP model, no difference was observed on the total time taken to chart medication orders between rules based on these two models. CONCLUSIONS Both, SNP- and allele-based models, can be used effectively for representing genetic test results in the EHR without impacting clinical decision support systems. While storing and reporting genetic test results as alleles allow for the construction of simpler decision-support rules, and make it easier to present these results to clinicians, SNP-based model can retain a greater amount of information that could be useful for future reinterpretation.

[1]  L. Kaminsky,et al.  Human P450 metabolism of warfarin. , 1997, Pharmacology & therapeutics.

[2]  Magnus Ingelman-Sundberg,et al.  CYPalleles: a web page for nomenclature of human cytochrome P450 alleles. , 2002, Drug metabolism and pharmacokinetics.

[3]  Joyce A. Mitchell,et al.  Status of clinical gene sequencing data reporting and associated risks for information loss , 2007, J. Biomed. Informatics.

[4]  V. Maojo,et al.  Integrating Genomics into Health Information Systems , 2002, Methods of Information in Medicine.

[5]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.

[6]  J D Horton,et al.  Warfarin therapy: evolving strategies in anticoagulation. , 1999, American family physician.

[7]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[8]  R. Altman,et al.  PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. , 2005, Methods in molecular biology.

[9]  H Furuya,et al.  Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. , 1995, Pharmacogenetics.

[10]  R G Bell,et al.  Mechanism of action of warfarin. Warfarin and metabolism of vitamin K 1 . , 1972, Biochemistry.

[11]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[12]  M. Hoffman,et al.  The Clinical Bioinformatics Ontology: A Curated Semantic Network Utilizing RefSeq Information , 2004, Pacific Symposium on Biocomputing.

[13]  Amnon Shabo,et al.  The seventh layer of the clinical-genomics information infrastructure , 2007, IBM Syst. J..

[14]  A T McCray,et al.  From Phenotype to Genotype: Issues in Navigating the Available Information Resources , 2003, Methods of Information in Medicine.

[15]  F. Collins,et al.  A vision for the future of genomics research , 2003, Nature.

[16]  C. McDonald,et al.  LOINC, a universal standard for identifying laboratory observations: a 5-year update. , 2003, Clinical chemistry.

[17]  M H Tarbit,et al.  Genetic analysis of the human cytochrome P450 CYP2C9 locus. , 1996, Pharmacogenetics.

[18]  J. Bonfield,et al.  Finishing the euchromatic sequence of the human genome , 2004, Nature.

[19]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[20]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[21]  F. Collins,et al.  Welcome to the genomic era. , 2003, The New England journal of medicine.

[22]  H. Echizen,et al.  Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin , 2003, The Pharmacogenomics Journal.

[23]  Joyce A. Mitchell,et al.  The impact of genomics on E-health. , 2004, Studies in health technology and informatics.